Get the Stockscreener App
27.59
0.48%
0.135
Agios Pharmaceuticals Inc stock is traded at $27.59, with a volume of 551.72K.
It is up +0.48% in the last 24 hours and down -0.53% over the past month.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
See More
Previous Close:
$27.45
Open:
$27.34
24h Volume:
551.72K
Relative Volume:
0.38
Market Cap:
$1.61B
Revenue:
$32.87M
Net Income/Loss:
$674.31M
P/E Ratio:
2.4283
EPS:
11.36
Net Cash Flow:
$-330.11M
1W Performance:
+0.92%
1M Performance:
-0.53%
6M Performance:
-23.53%
1Y Performance:
-17.76%
1-Day Range:
$27.10
$27.67
1-Week Range:
$26.54
$27.67
52-Week Range:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals Inc
Sector
Industry
Phone
617-649-8600
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
27.58 | 1.60B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.92 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.55 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
405.75 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
801.69 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.75 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-20-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-24-25 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-27-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-03-23 | Initiated | Piper Sandler | Overweight |
| Nov-17-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-27-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Jul-30-21 | Downgrade | Goldman | Neutral → Sell |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-01-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-26-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-22-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-26-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Feb-15-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-25-18 | Initiated | Leerink Partners | Mkt Perform |
| May-23-18 | Initiated | Citigroup | Buy |
| Apr-11-18 | Reiterated | Credit Suisse | Outperform |
| Feb-15-18 | Reiterated | Needham | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-10-17 | Reiterated | Needham | Buy |
| Aug-08-17 | Reiterated | SunTrust | Buy |
| Aug-02-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-17 | Downgrade | Janney | Buy → Neutral |
| Jan-17-17 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-24-16 | Initiated | Needham | Buy |
| Jun-13-16 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-16 | Reiterated | SunTrust | Buy |
View All
Agios Pharmaceuticals Inc Stock (AGIO) Latest News
JP Morgan Raises Price Target for Agios Pharmaceuticals (AGIO) to $25 | AGIO Stock News - GuruFocus
Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - The Manila Times
Insider Selling: Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells 2,932 Shares of Stock - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) CFO Sells $79,427.88 in Stock - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) CEO Brian Goff Sells 18,703 Shares - MarketBeat
Agios pharma chief legal officer Burns sells $79k in stock - Investing.com Canada
Agios pharma chief medical officer Gheuens sells $79k in stock - Investing.com Canada
Agios Pharmaceuticals CEO Goff sells $506,663 in stock By Investing.com - Investing.com Australia
Agios Pharmaceuticals CEO Goff sells $506,663 in stock - Investing.com
Jones Cecilia, Agios Pharmaceuticals CFO, sells $79k in stock By Investing.com - Investing.com UK
Agios pharma CCO Milanova sells $79k in stock after option exercise - Investing.com UK
Agios Pharma shares jump 16% as US FDA expands approval for blood disorder drug - MSN
Momentum Indicator Shows Bearish Divergence in Sylvan Plyboard India LimitedRisk-Reward Ratio Analysis & Stay Ahead With Daily Market Discussions - earlytimes.in
How Agios Pharmaceuticals Inc. stock valuations compare to rivalsStock Correlation Metrics & Free Superior Profit Margins - bollywoodhelpline.com
Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat - MSN
Geopolitics Watch: Is Agios Pharmaceuticals Inc 8AP stock attractive post correctionLayoff News & Low Risk Entry Point Tips - moha.gov.vn
FDA approves Agios’ AQVESME (mitapivat) for the treatment of anemia in adults - MSN
Agios Pharmaceuticals (NASDAQ:AGIO) Shares Down 5.3%Should You Sell? - MarketBeat
Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday - Benzinga
AGIO: Analyst Andrew Berens Raises Agios Pharmaceuticals Price T - GuruFocus
Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains? - Yahoo Finance
BofA Securities raises Agios Pharma stock price target on FDA approval - Investing.com India
Agios (AGIO) Gets 18.6% Boost from Aqvesme OK - Finviz
B of A Securities Maintains Agios Pharmaceuticals (AGIO) Buy Recommendation - MSN
Agios Pharmaceuticals price target raised to $34 from $32 at BofA - Yahoo Finance
Agios Stock (+19%): AQVESME Thalassemia Approval Ignites Re-Rate - Trefis
Agios Pharma shares jump as US FDA expands approval for blood disorder drug - wibqam.com
Why Agios Pharmaceuticals (AGIO) Is Up 14.6% After First-in-Class Thalassemia Drug AQVESME Wins FDA Approval - Sahm
Agios Pharma stock price target raised to $62 from $48 at H.C. Wainwright - Investing.com India
Truist Financial Forecasts Strong Price Appreciation for Agios Pharmaceuticals (NASDAQ:AGIO) Stock - MarketBeat
Agios Pharma Stock: A Buy After FDA Approves Aqvesme (NASDAQ:AGIO) - Seeking Alpha
Here's Why Shares in Agios Pharmaceuticals Popped Today - AOL.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Here's Why Shares in Agios Pharmaceuticals Popped Today - The Motley Fool
Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta ThalassemiaSlideshow (NASDAQ:AGIO) 2025-12-24 - Seeking Alpha
First oral anemia treatment across thalassaemia types approved in USA - The Pharma Letter
AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label - Eastern Progress
Agios Pharma shares jump as US FDA expands approval for its blood disorder drug - Yahoo Finance
Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Up on Analyst Upgrade - MarketBeat
The $1.7 Billion Pivot: Agios Pharmaceuticals (AGIO) and the New Frontier of Oral Thalassemia Therapy - FinancialContent
AGIO (Agios Pharmaceuticals) EV-to-OCF : -1.89 (As of Dec. 24, 2025) - GuruFocus
Agios (AGIO) Surges 12% Following FDA Approval of New Thalassemi - GuruFocus
Agios Shares Rise After FDA Approves Aqvesme to Treat Anemia in Thalassemia Patients - marketscreener.com
Why Did AGIO Stock Surge 14% Today? - Stocktwits
Agios Pharmaceuticals stock soars after FDA approves AQVESME for thalassemia - Investing.com Canada
Transcript : Agios Pharmaceuticals, Inc.Special Call - marketscreener.com
Bank of America Issues Positive Forecast for Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price - MarketBeat
Agios Pharmaceuticals Inc Stock (AGIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Agios Pharmaceuticals Inc Stock (AGIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Burns James William | Chief Legal Officer |
Dec 30 '25 |
Option Exercise |
0.00 |
6,000 |
0 |
34,650 |
| Burns James William | Chief Legal Officer |
Dec 30 '25 |
Sale |
27.09 |
2,932 |
79,428 |
31,718 |
| Goff Brian | Chief Executive Officer |
Dec 30 '25 |
Option Exercise |
0.00 |
38,278 |
0 |
149,333 |
| Goff Brian | Chief Executive Officer |
Dec 30 '25 |
Sale |
27.09 |
18,703 |
506,664 |
136,583 |
| Gheuens Sarah | Chief Medical Officer |
Dec 30 '25 |
Option Exercise |
0.00 |
6,000 |
0 |
67,727 |
| Gheuens Sarah | Chief Medical Officer |
Dec 30 '25 |
Sale |
27.09 |
2,932 |
79,428 |
64,795 |
| Milanova Tsveta | Chief Commercial Officer |
Dec 30 '25 |
Option Exercise |
0.00 |
6,000 |
0 |
32,122 |
| Milanova Tsveta | Chief Commercial Officer |
Dec 30 '25 |
Sale |
27.09 |
2,932 |
79,428 |
29,190 |
| Jones Cecilia | Chief Financial Officer |
Dec 30 '25 |
Option Exercise |
0.00 |
6,000 |
0 |
40,326 |
| Jones Cecilia | Chief Financial Officer |
Dec 30 '25 |
Sale |
27.09 |
2,932 |
79,428 |
37,394 |
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):